ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±¹ù»ÀÁᣩ¿ËÈÕ£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚÒ»Ò½Ôº³¬Éùҽѧ¿ÆÐ»ÏþÑà½ÌÊÚÍŶÓÓëngµç×ÓÓÎÏ·ÖÊÁÏ¿ÆÑ§Ó빤³ÌѧԺ˧ÐÄÌνÌÊÚÍŶӵĽ»Ö¯Ñ§¿ÆÏàÖúÑо¿Ð§¹ûÔÚ¸ßÖÊÁ¿ÔÓÖ¾Nano TodayÉÏÒÔresearch articleµÄÐÎʽ½ÒÏþ¡£¡£¡£ ¸ÃÑо¿ÎªÒÔPD-1/PD-L1Ϊ°ÐµãµÄRFAºóÖ×Áö×ÛºÏÖÎÁÆÌṩÁËÀíÂÛÒÀ¾Ý£¬ÎªÊÜÀ§ÓÚÃâÒßÒ©ÎïÄÍÒ©ºÍ¶¾¸±×÷ÓõÄÖ×Áö»¼Õß´øÀ´ÁËеÄÏ£Íû£¬¶Ô¸ÄÉÆÖ×ÁöRFAÊõºóÔ¤ºó¾ßÓÐDZÔÚµÄÁÙ´²¼ÛÖµ¡£¡£¡£
É䯵ÏûÈÚ£¨Radiofrequency ablation, RFA£©ÒòÆä΢´´¡¢¡¢¡¢ÁÆÐ§È·ÇС¢¡¢¡¢×¡ÔºÊ±¼ä¶ÌµÈÓÅÊÆ£¬ÒÑ¿ªÕ¹ÎªÖ×Áö×ÛºÏÖÎÁƵÄÖ÷Òª×é³É²¿·Ö£¬ÆÕ±éÓ¦ÓÃÓÚÔ·¢»òÕß×ªÒÆÐÔ¸ÎÔàÖ×ÁöµÈʵÌåÖ×ÁöµÄÖÎÁÆ¡£¡£¡£¿ÉÊÇ£¬¹ØÓÚÖ×ÁöÖ±¾¶´óÓÚ3 cm¡¢¡¢¡¢ÐÎ̬²»¹æÔò¡¢¡¢¡¢Î»ÓÚÖ÷ÒªÔàÆ÷¼°´óѪ¹ÜÅÔµÄÖ×Áö£¬RFAÍùÍùÄÑÒÔµÖ´ïÍêÈ«ÏûÈÚ£¬Êǵ¼ÖÂÖ×Áö¸´·¢Ï£ÍûµÄÖ÷ÒªÔÒò¡£¡£¡£ÓëÍâ¿ÆÊÖÊõÇгý²î±ðµÄÊÇ£¬RFAÊÇͨ¹ýÈÈЧӦʹÖ×Áö±¬·¢ÔλÄý¹ÌÐÔ»µËÀ£¬ÔÚÕâ¸öÀú³ÌÖУ¬¿É´Ù·¢´ó×ÚÖ×ÁöÏà¹Ø¿¹ÔÊÍ·Å£¬ÓÕµ¼»úÌ屬·¢¿¹Ö×ÁöÃâÒßЧӦ¡£¡£¡£È»¶ø£¬Ð»ÏþÑà½ÌÊÚÍŶÓÔÚ¶àÄêÖ×ÁöÏûÈÚµÄÁÙ´²Êµ¼ù¼°Ïà¹ØÑо¿Öз¢Ã÷£¬Ö×ÁöÏûÈÚÊõºóËù±¬·¢µÄ¿¹Ö×ÁöÃâÒßЧӦȱ·¦ÒÔÒÖÖÆÊ£ÓàÖ×Áö¸´·¢£¬ÇÒ²¿·Ö»¼Õß·ºÆðÖ×Áö¶ñ»¯Ï£Íû£¬ÏÖÔÚÏà¹Ø»úÖÆÉÐδÃ÷È·¡£¡£¡£
½üÄêÀ´£¬³ÌÐòÐÔéæÃüÊÜÌå-1/³ÌÐòÐÔéæÃüÅäÌå-1£¨Programmed cell death protein-1/Programmed cell death ligand 1, PD-1/PD-L1£©Þ׿¹ÖÎÁÆÔÚÖ×ÁöÃâÒßÖÎÁÆÁìÓòÈ¡µÃÁËÖØ´óÍ»ÆÆ¡£¡£¡£Ð»ÏþÑà½ÌÊÚÍŶÓÔÚ²»ÍêÈ«ÏûÈÚÖ×Áö¶¯ÎïÄ£×ÓÖз¢Ã÷£¬ÏûÈÚÊõºóÊ£ÓàÖ×ÁöÍâòPD-L1ÏÔÖøÉϵ÷£¬ÕâÅú×¢PD-1/PD-L1¼ÓÈëÏûÈÚÊõºóÊ£ÓàÖ×Áö±¬·¢ÃâÒßÌÓÒÝ¡£¡£¡£È»¶ø£¬»ØÊ×ÐÔÑо¿ºÍ¶¯ÎïʵÑéÊý¾Ý¾ùÅú×¢£¬¼òµ¥PD-1/PD-L1Þ׿¹ÖÎÁƶÔRFAÊõºóÖ×ÁöÏ£ÍûÁÆÐ§Ç·¼Ñ¡£¡£¡£Ñо¿ÍŶӽøÒ»²½ÆÊÎö·¢Ã÷£¬RFAÊõºóÊ£ÓàÖ×ÁöSTINGͨ·¼¤»îȱ·¦£¬µ¼ÖÂÊ£ÓàÖ×ÁöÖÐTÁܰÍϸ°û½þÈóÉÙ£¬ÊÇPD-1/PD-L1Þ׿¹ÖÎÁƲ»¼ÑµÄ¿ÉÄÜÔÒò¡£¡£¡£
¿ÉÊÇ£¬ÏÖÔÚSTINGͨ·¼¤»î¼ÁºÍPD-1/PD-L1Þ׿¹¿¹ÌåÁªºÏÖÎÁÆÈÔ±£´æÄÑÌ⣺£ºPD-1/PD-L1Þ׿¹¿¹ÌåºÍSTINGͨ·¼¤»îÒ©ÎïµÄÁÙ´²Ó¦ÓÃÈÔÊÜÏÞÓÚÒòÒ©Îï·Ç°ÐÏòÔËË͵¼ÖµÄÃâÒßÏà¹Ø¶¾¸±×÷Óᣡ£¡£±ðµÄ£¬PD-L1¿¹Ìå¼°STING¼¤»î¼ÁµÄ×÷ÓÃλµã»®·ÖλÓÚÖ×Áöϸ°ûÍâò¼°¿¹ÔÌá³Êϸ°ûÄÚ£¬ÐèÒªµÖ´ïÑÇϸ°û²ãÃæ¾«×¼µÝËͲſÉʵÏÖÒ©ÎïµÄÓÐÓÃÐͬ×÷Óᣡ£¡£
Ϊ½â¾öÕâÒ»ÄÑÌ⣬¸ÃÑо¿½ÓÄÉ˧ÐÄÌνÌÊÚÍŶÓÑз¢µÄÉúÎïÏàÈÝÐÔµÄÁ×Ö¬ÖÊÁϼ°ÆäÍŶÓÖÆ±¸µÄÒ»ÖÖpHºÍMMP-2Ë«ÖØÃô¸ÐµÄÄÉÃ×ÄÒÅÝ£¬ÊµÏÖÁËÑÇϸ°ûˮƽµÄ³ÌÐòÐÔ¾«×¼Ò©Îï¿ØÊÍ¡£¡£¡£ÄÉÃ×ÄÒÅݵÄˮǻ°ü¹üSTING¼¤»î¼Á£¬±í²ãͨ¹ýMMP-2Ãô¸ÐµÄ¶ÌëÄPLGVRGżÁª¿¹PD-L1¿¹Ìå¡£¡£¡£Í¬Ê±£¬Í¨¹ýËáÃô¸ÐµÄõ£°·¼üżÁªPEG£¬¿É×è°¿¹PD-L1¿¹ÌåÓëPD-L1ÑôÐÔµÄÕý³£×éÖ¯Á¬Ïµ£¬´Ó¶ø¸³ÓèÁËÄÉÃ×Ò©ÎïµÄÒþÉíÐÔÄÜ¡£¡£¡£µ±ÄÉÃ×Ò©Î︻¼¯ÔÚÖ×Áö×éÖ¯Öкó£¬PEG¿Ç²ãºÍ¿¹Ìå»®·ÖÔÚÊ£ÓàÖ×Áö΢ÇéÐεÄËáÐÔÌõ¼þºÍMMP-2µÄ´¥·¢ÏϹ½ÁÎÊÍ·Å¡£¡£¡£¶øPEGºÍ¿¹ÌåµÄÊÍ·ÅʹµÃÄÒÅݵÄÍâòµçλ´Ó¸ºµçÐԷתΪÕýµçÐÔ£¬Ôö½øÁËÔØSTING¼¤»î¼ÁÄÒÅݱ»¿¹ÔÌá³Êϸ°ûÄÚÍÌ£¬Ê¹µÃSTING¼¤»î¼ÁÔÚ°ûÖÊÓÐÓü¤»îSTINGͨ·¡£¡£¡£ÌåÍâºÍºÉÁöСÊóµÄʵÑéÊý¾Ý¾ùÅú×¢£¬¸Ãϵͳ¿Éͨ¹ý¼¤»îÊ÷ͻ״ϸ°û£¬ÔöÌí¿¹Ö×ÁöTÁܰÍϸ°ûµÄÁöÄÚ½þÈ󣬴ӶøÏÔÖøÒÖÖÆRFAÊõºóÊ£ÓàÖ×ÁöµÄÏ£Íû¡£¡£¡£±ðµÄ£¬Óë·ÇPEGÆÁÕϵÄÄÉÃ×Ò©Îï×éÏà±È£¬PEGÆÁÕϲãÏÔÖø½µµÍÁËSTING¼¤»î¼ÁºÍ¿¹PD-L1¿¹ÌåÖÎÁƵ¼ÖµĸÎÔà¶¾ÐÔ¡£¡£¡£

MMP-2/pHË«Ãô¸ÐÖ¬ÖÊÌå¹²ÔØSTING¼¤»î¼ÁºÍ¿¹PD-L1¿¹ÌåÐͬ¼¤»îÉ䯵ÏûÈÚÊõºó¿¹Ö×ÁöÃâÒߣ¬ÒÖÖÆÊ£ÓàÖ×ÁöÏ£ÍûºÍ¸´·¢
¸ÃÑо¿Êܵ½¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÖØ´óÑо¿ÍýÏëÏîÄ¿¡¢¡¢¡¢¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÃæÉÏÏîÄ¿¡¢¡¢¡¢¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÇàÄêÏîÄ¿¼°¹ãÖÝÊÐÖØµãÁìÓòÑз¢ÍýÏëÏîÄ¿µÈ×ÊÖú¡£¡£¡£ÂÛÎÄÎÊÌâΪ¡°Nanodrug shows spatiotemporally controlled release of anti-PD-L1 antibody and STING agonist to effectively inhibit tumor progression after radiofrequency ablation¡±¡£¡£¡£ngµç×ÓÓÎÏ·Á¥ÊôµÚһҽԺΪÂÛÎĵÚÒ»µ¥Î»¼°Í¨Ñ¶µ¥Î»£¬Ð»ÏþÑà½ÌÊÚ¡¢¡¢¡¢Ë§ÐÄÌνÌÊÚ¡¢¡¢¡¢ÐìÃ÷¸±½ÌÊÚ¼°ÕÅ´ºÑô¸±Ñо¿Ô±ÎªÅäºÏͨѶ×÷Õߣ¬ngµç×ÓÓÎÏ·Á¥ÊôµÚÒ»Ò½Ôº²©Ê¿ºó¹ù»ÀÁá¡¢¡¢¡¢ngµç×ÓÓÎÏ·Á¥ÊôµÚÆßÒ½ÔºÖúÀíÑо¿Ô±»Æ½ðÉú¼°ngµç×ÓÓÎÏ·Á¥ÊôµÚÒ»Ò½ÔºÖúÀíÑо¿Ô±Ì·ÑóΪÅäºÏµÚÒ»×÷Õß¡£¡£¡£
ÂÛÎÄÁ´½Ó£º£ºhttps://www.sciencedirect.com/science/article/pii/S1748013222000524